Laboratory Billing Services: How to Maximize Reimbursement and Avoid the Compliance Traps

Laboratory billing is one of the most specialized areas in medical billing — and one of the most commonly done incorrectly. The rules that govern what a lab can bill, to whom, and at what rate are fundamentally different from the rules that govern physician services. Practices that approach lab billing the same way they approach office visit billing tend to have high denial rates, compliance exposure, and significant unrealized revenue.

This guide covers the core billing framework for clinical laboratories — whether you're running an independent lab, a hospital-affiliated lab, or an in-house physician office lab (POL).

PAMA Rates: The Medicare Fee Schedule for Lab Services

Clinical laboratory services billed to Medicare are reimbursed under the Clinical Laboratory Fee Schedule (CLFS), which is governed by the Protecting Access to Medicare Act (PAMA). Unlike physician services, which are reimbursed based on RVUs, lab tests are paid at a flat rate per test.

PAMA rates are updated periodically based on private payer rates reported by labs. The resulting rates are lower than historical Medicare rates for many tests — which has significantly impacted independent lab revenue over the past several years.

Key implication: Lab billing must be precise. At $8–12 per chemistry panel, there is no margin for billing errors, write-offs, or denials that could have been prevented.

Local Coverage Determinations (LCDs) — The Most Common Denial Source

A Local Coverage Determination (LCD) is a Medicare Administrative Contractor (MAC) policy that defines when a specific test is covered — what diagnoses justify the test, and under what clinical circumstances.

For labs in California, the relevant MAC is Noridian (Jurisdiction E for Part B). Noridian's LCDs define which ICD-10 diagnosis codes are acceptable for billing specific lab tests.

How LCD denials happen:

A physician orders a comprehensive metabolic panel (CMP, CPT 80053). The lab performs the test and bills Medicare. If the diagnosis code on the order doesn't match an ICD-10 code listed in Noridian's LCD for 80053, the claim is denied as "not medically necessary."

The lab performed a legitimate test ordered by a licensed physician — and doesn't get paid because the diagnosis wasn't documented to match the LCD criteria.

The fix: Labs must maintain current LCD reference guides for each test they routinely perform. Before billing a claim, the diagnosis code on the requisition must be verified against the applicable LCD. When the diagnosis doesn't meet LCD criteria, the patient must be issued an Advance Beneficiary Notice (ABN) before the test is performed.

The ABN: Critical Compliance Document

An Advance Beneficiary Notice of Noncoverage (ABN) is a notice given to a Medicare patient before a non-covered service is performed. It informs the patient that Medicare may not cover the test, and that the patient will be responsible for payment if Medicare denies the claim.

When an ABN is required:

• When the ordered test does not meet the applicable LCD criteria
• When the test is excluded from Medicare coverage entirely
• When the frequency of testing exceeds Medicare's allowable frequency

When an ABN is NOT valid:

• Given to a patient after the test is performed
• Used as a blanket waiver (must be test-specific)
• Used for tests that are categorically non-covered (ABN doesn't create patient liability for these — a different waiver form applies)

Labs that collect payment from Medicare patients for tests without a properly issued ABN face significant compliance exposure. Conversely, labs that issue ABNs appropriately can legally collect from the patient for non-covered services.

Reflexive and Add-On Testing: When You Can (and Can't) Bill

Many labs perform reflex testing — when an initial test result triggers a follow-on test automatically per the standing order. For example, if a urinalysis shows bacteria, a urine culture is automatically performed.

Billing rule: Reflex testing is billable only if the physician's original order included standing instructions for the reflex, or if the lab obtains separate authorization. You cannot unilaterally perform additional testing beyond what was ordered and bill for it — even if clinically logical.

Add-on testing (tests added by the lab without physician direction) is generally not billable to Medicare or commercial payers and creates compliance risk.

Split Billing and the Physician Office Lab

When a physician practice has an in-house POL, they can bill Medicare for tests they perform in-house under their CLIA certificate — but only for tests within their CLIA certification level.

CLIA certificate levels:

• Certificate of Waiver — waived tests only (glucose, strep, flu, urinalysis by dipstick)
• Certificate for Provider-Performed Microscopy — adds microscopic urinalysis and certain other tests
• Certificate of Compliance / Accreditation — moderate and high complexity tests

A POL with a Certificate of Waiver billing for a CBC (which is a moderate-complexity test) is a compliance violation. The test must be performed within the CLIA scope.

Tests the POL sends to a reference lab must not be billed by the ordering physician unless they're billing only for the interpretation of results — with modifier 26 — and only if they actually performed and documented the interpretation separately from the reference lab's report.

Billing for Molecular and Genetic Testing

Molecular diagnostic and genetic testing is a growing area of lab revenue — and one of the most scrutinized by payers.

Key issues:

• Prior authorization is increasingly required by commercial payers for molecular panels, genetic panels, and pharmacogenomics testing
• Many molecular tests are only covered under very specific LCD-defined criteria — hereditary cancer syndromes, specific diagnoses, prior treatment failure
• Billing for a molecular panel when only individual gene tests were ordered (or vice versa) is a common coding error

Molecular tests use codes from the Tier 1 (81105–81383), Tier 2 (81400–81479), and Proprietary Laboratory Analyses (PLA) code sets. PLA codes are specific to particular commercial tests — billing with a generic CPT when a PLA code exists is technically incorrect.

Toxicology Billing: High Scrutiny, High Value

Toxicology testing — particularly urine drug testing ordered by behavioral health, addiction medicine, pain management, and primary care practices — is both high-volume and high-scrutiny.

Two-step billing model:

1. Presumptive testing (immunoassay screen) — CPT G0480–G0483 (CMS codes) or 80305–80307
2. Definitive testing (confirmation by LC-MS/MS) — CPT 80320–80377 (specific drug class codes)

Billing definitive testing without documented medical necessity, or billing confirmatory tests at higher code levels than performed, has been a major area of False Claims Act enforcement actions against independent labs.

If your lab does toxicology billing, the documentation requirements and billing compliance standards are significantly higher than for routine chemistry panels.

What the Right Lab Billing Operation Looks Like

A well-managed lab billing operation:

1. Maintains current LCD reference files for all routinely billed tests — updated when Noridian or the applicable MAC revises policies
2. Issues ABNs proactively when diagnoses on requisitions don't meet LCD criteria — before testing, not after
3. Verifies CLIA scope compliance for in-house POL billing
4. Tracks authorization requirements for molecular and genetic panels by payer
5. Reconciles the complete CLFS fee schedule against actual reimbursements to catch payer underpayments
6. Runs monthly denial analysis by test code and diagnosis code to identify systematic LCD mismatches

---

Running a lab and dealing with a high volume of "not medically necessary" denials? Talk to our team — lab billing is a specialty within a specialty, and we know exactly where the problems are.